These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23392805)

  • 1. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
    Zhou DH; Yang LN; Roder C; Kalthoff H; Trauzold A
    Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):94-8. PubMed ID: 23392805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell.
    Zhou DH; Trauzold A; Röder C; Pan G; Zheng C; Kalthoff H
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):201-9. PubMed ID: 18397859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
    Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
    Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.
    Hinz S; Trauzold A; Boenicke L; Sandberg C; Beckmann S; Bayer E; Walczak H; Kalthoff H; Ungefroren H
    Oncogene; 2000 Nov; 19(48):5477-86. PubMed ID: 11114725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
    Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
    Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
    Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
    Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
    Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
    Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells.
    Trauzold A; Röder C; Sipos B; Karsten K; Arlt A; Jiang P; Martin-Subero JI; Siegmund D; Müerköster S; Pagerols-Raluy L; Siebert R; Wajant H; Kalthoff H
    FASEB J; 2005 Apr; 19(6):620-2. PubMed ID: 15670977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells.
    Willms A; Schittek H; Rahn S; Sosna J; Mert U; Adam D; Trauzold A
    PLoS One; 2019; 14(4):e0214847. PubMed ID: 30947287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.
    Büneker CK; Yu R; Deedigan L; Mohr A; Zwacka RM
    Cancer Lett; 2012 Mar; 316(2):168-77. PubMed ID: 22104728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.
    Song JJ; An JY; Kwon YT; Lee YJ
    J Biol Chem; 2007 Jan; 282(1):319-28. PubMed ID: 17110373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma.
    Röder C; Trauzold A; Kalthoff H
    Eur J Cell Biol; 2011; 90(6-7):450-5. PubMed ID: 21129814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma.
    Hetschko H; Voss V; Horn S; Seifert V; Prehn JH; Kögel D
    J Neurooncol; 2008 Feb; 86(3):265-72. PubMed ID: 17924059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.